Thorsen L I, Brosstad F, Solum N O, Stormorken H
Scand J Haematol. 1986 Feb;36(2):203-10. doi: 10.1111/j.1600-0609.1986.tb00829.x.
Interactions of the dysfibrinogen Oslo I with platelets were investigated. This fibrinogen is a B beta-chain variant with faster than normal fibrin monomer polymerization. Fibrinogen Oslo I acted more efficiently in ADP-induced platelet aggregation, and bound to gel-filtered platelets with a higher affinity constant than did normal fibrinogen. At all concentrations more fibrinogen molecules became bound per platelet with the dysfibrinogen than with normal fibrinogen, both when the fibrinogens were tested separately or as a mixture using 125I or 131I to label the two types. At high concentrations this was probably due to ligand polymerization of the dysfibrinogen. These observations indicate that the increased cofactor function in platelet aggregation may be related to the increased affinity of the dysfibrinogen for the platelets.
对异常纤维蛋白原奥斯陆I与血小板的相互作用进行了研究。这种纤维蛋白原是一种Bβ链变体,其纤维蛋白单体聚合速度比正常情况快。奥斯陆I型纤维蛋白原在ADP诱导的血小板聚集中作用更有效,并且与凝胶过滤后的血小板结合时,其亲和常数高于正常纤维蛋白原。在所有浓度下,无论单独测试纤维蛋白原还是将它们作为混合物使用125I或131I标记这两种类型时,与正常纤维蛋白原相比,异常纤维蛋白原与每个血小板结合的分子更多。在高浓度下,这可能是由于异常纤维蛋白原的配体聚合。这些观察结果表明,血小板聚集中辅助因子功能的增加可能与异常纤维蛋白原对血小板亲和力的增加有关。